Arnaud Nativel, doctoral student, is conducting his research at the Montpellier Cancer Research Institute (IRCM), INSERM U1194, under the supervision of Dr. Romain Larive. The topic of his dissertation is: “Hybrid artificial intelligence models for predicting response to treatments for advanced cutaneous melanoma” (PredictIAmel).
He summarized his topic: “MAPK inhibitors (MAPKi) and immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced melanoma. However, the presence of primary or acquired resistance leads to variable efficacy. Patients with BRAFV600-mutated melanoma have a high response rate to MAPKis at the start of treatment, and those treated with ICIs have a more durable response. Treatment selection therefore requires a reliable prediction of the response and its duration. The goal of the project is to develop a hybrid artificial intelligence model that integrates machine learning and mechanistic modeling of cancer biological networks to predict a tumor’s therapeutic response based on its clinical and multiomic characteristics.”
By supporting this thesis project over the next three years, the Jean PAUFIQUE Corporate Foundation reaffirms its commitment to innovative research that benefits patients and medical science advances.
